News

Cupron Performance Additives (“Cupron”) announces new distribution relationship with Palmer Holland

Cupron Performance Additives (Cupron) announced today the launch of an exclusive distribution agreement with Palmer Holland, leading North American distributor of specialty additives for the engineered materials marketplace. Palmer Holland will distribute Cupron’s copper-based antimicrobial and anti-odor technologies into plastics, films, foams, and polymeric systems throughout North America. The Cupron line effectively complements Palmer Holland’s already best-in-class portfolio of specialty additives for plastics.

The Cupron/Palmer Holland partnership offers customers immediate value backed by cutting-edge science and renowned service. Palmer Holland’s deep knowledge of plastic, film, and foam applications will combine synergistically with Cupron’s most time-tested, well-proven antimicrobial and anti-odor technologies. Cupron products are available now for purchase and sampling from Palmer Holland.

Commenting on the partnership, Chris Andrews, Cupron’s Chief Executive Officer, said,

“We were drawn to Palmer Holland’s reputation for its longstanding differentiated market service. Extensive due diligence only validated our assumptions. Where it matters most, our companies overlap in culture and market objectives. Our thanks to Palmer Holland’s talented sales professionals for their vision and enthusiasm during scale-up discussions. We send gratitude and congratulations to Palmer Holland leaders Vince Misiti, Tony Denton, and Jim Norris for their stewardship of a truly great organization.”

Jim Norris, Market Manager for Engineered Materials at Palmer Holland, commented,

“Palmer Holland’s Engineered Materials Business continues to set itself apart with a distribution model designed to deliver unmatched value to suppliers and customers alike. Our new partnership with Cupron is a perfect fit with our strategy of championing specialty additives and modifiers that redefine performance standards. Cupron brings to the plastic-adjacent market a one-of-a-kind technology that combines proven antimicrobial, biocidal, and antifungal protection with a strong sustainability profile—addressing critical needs in product safety, durability, and environmental responsibility.

Through this collaboration, Palmer Holland will connect Cupron’s innovation with leading compounders and masterbatch producers, enabling the creation of next-generation materials that perform better, last longer, and contribute to a healthier planet.”

 

Read more here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation